Objective: Since decades antibodies have been intensively used in enzyme linked immunosorbent assays (ELISA) for quantification for instance of drugs, metabolites and microorganisms. During the recent years also therapeutic medicinal products have been launched with monoclonal antibodies as the active ingredient, e.g. the anti-cancer drug Cetuximab from Merck KGaA. Therefore, it is reasonable to assume that a similar use of anti-bodies in dentistry would be reasonable as well. So, monoclonal antibodies could be used for the quantification of pathogenic oral bacteria which is shown by a new diagnostic device for caries risk assessment. In addition, the high specificity of monoclonal antibodies for binding to corresponding pathogens could be employed for the development of specific therapeutic products.
Conclusion: It is quite clear that the oral cavity will ever be populated by microorganisms. The pathogenic ones could be detected by the use of antibody-based diagnostics. Eventually, antibodies could be used to remove pathogenic microorganisms out of a biofilm which thus might be turned from a bad plaque to a good plaque.